Myasthenia Gravis and Thymoma Authors: Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li Published: 2026 ABSTRACT ABSTRACTThymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG. Historical estimates suggest that thymoma associated MG (TAMG) represents roughly 15%–20% of MG patients, although the proportion of TAMG has been decreasing. Virtually all TAMG patients are seropositive for AChR antibodies. In comparison to MG without thymoma, TAMG is mostly generalized and more refractory to treatment. Chest CT with contrast is the imaging modality of choice in evaluating thymoma, while MRI and PET scan may have an ancillary role in defining tumor invasiveness, staging and further differentiating thymoma from other mediastinal masses. Surgical resection should be considered for all patients with thymoma, regardless of MG status as all thymomas are malignant. Minimally invasive surgery appears equally efficacious as sternotomy for patients with early stage thymoma, and has become more prevalent due to its lower complication rates. Preoperative optimization with intravenous immunoglobulin or plasmapheresis is unnecessary in patients with stable MG. New onset MG could occur in thymoma patients following thymectomy, and the presence of AChR antibody preoperatively may be a predictive risk factor. Patients with advanced stage thymoma may require neoadjuvant or adjuvant chemotherapy and/or radiation, typically managed in a multidisciplinary setting. The recurrence rate of thymoma is mainly dependent upon its pathological stage, and worsening myasthenic symptoms may herald a recurrence of thymoma. Abbreviations acetylcholine receptor autoimmune regulator cyclophosphamide, doxorubicin, and cisplatin PET imaging with [18F]‐fluorodeoxyglucose human chorionic gonadotropin intravenous immunoglobulin lactate dehydrogenase myasthenia gravis Myasthenia Gravis Foundation of America neuromyotonia non‐thymomatous myasthenia gravis postoperative myasthenic crisis ryanodine receptor standard uptake value thymoma associated myasthenia gravis video‐assisted thoracoscopic surgery World Health Organization Introduction Thymoma, a tumor derived from thymic epithelial cells, is the most common tumor of the anterior mediastinum. Thymoma is linked to the development of paraneoplastic myasthenia gravis (MG), and the presence of thymoma in patients with MG has important implications for disease severity, treatment options, and outcomes [1]. Pooled estimates indicate that roughly 15%–20% of patients with MG harbor a thymoma, herein referred to as thymoma associated myasthenia gravis (TAMG), and approximately 20%–30% of individuals with a thymoma show clinical signs of MG [2, 3, 4, 5, 6, 7]. There are five primary histological subtypes of thymoma outlined within the World Health Organization (WHO) classification system (Table 1) [8]. Type A tumors consist of oval spindle epithelial cells and are relatively lymphocyte depleted; type B tumors are comprised of round epithelioid cells mixed with varying amounts of non‐neoplastic lymphocytes, and type AB tumors contain both histological subtypes [8, 9]. The lymphocyte‐rich type B thymoma (B1, B2, and B3 subtypes) can support the maturation and export of helper T‐cells that recognize muscle‐specific antigens including the acetylcholine receptor (AChR) and thus are most often found in TAMG [10, 11, 12, 13]. Thymic carcinoma, another epithelial tumor formerly listed under thymoma, is a much more aggressive neoplasm, which is rarely associated with MG [6]. Based on the macroscopic and the microscopic invasion, thymoma is subdivided into four stages (I–IV) by the commonly used Masaoka–Koga system (Table 2) [14]. TABLE 1Epidemiological and clinicopathological features of thymoma [8].Thymoma type (WHO classification)Pathologic classificationAverage relative frequency (range)Male to female ratioMean myasthenia gravis frequency (range)Type A Medullary thymoma Spindle cell thymoma 11.5% (3.1%; 26.2%) 1:1.417% (0%; 33%)Type ABMixed thymoma 25% (15%; 43.0%) 1:1.418% (6%; 42%)Type B1 Lymphocyte‐rich thymoma Lymphocytic thymoma Predominantly cortical thymoma Organoid thymoma 17.5% (5.9%; 52.8%) 1:1.644% (7%; 70%)Type B2Cortical thymoma 26% (8.0%; 41.1%) 1:154% (24%; 71%)Type B3 Squamoid thymoma Well differentiated thymic carcinoma 16.0% (3.4%; 35.1%) 1:0.850% (25%; 65%)Micronodular—1.0%1.2:1RareMetaplastic—< 1.0%1:1.5Rare Epidemiological and clinicopathological features of thymoma [8]. Medullary thymoma Spindle cell thymoma 11.5% (3.1%; 26.2%) 25% (15%; 43.0%) Lymphocyte‐rich thymoma Lymphocytic thymoma Predominantly cortical thymoma Organoid thymoma 17.5% (5.9%; 52.8%) 26% (8.0%; 41.1%) Squamoid thymoma Well differentiated thymic carcinoma 16.0% (3.4%; 35.1%) TABLE 2Masaoka‐Koga staging of thymoma [14].Stage IMacroscopically and microscopically completely encapsulatedStage II Microscopic transcapsular invasionMacroscopic invasion into surrounding fatty tissue or grossly adherent to, but not through, mediastinal pleura or pericardium Stage IIIMacroscopic invasion into neighboring organs (e.g., pericardium, great vessels, lungs) Without invasion of great vesselsWith invasion of vessels Stage IV Pleural or pericardial disseminationLymphatic or hematogenous metastasis Masaoka‐Koga staging of thymoma [14]. Microscopic transcapsular invasion Microscopic transcapsular invasion Macroscopic invasion into surrounding fatty tissue or grossly adherent to, but not through, mediastinal pleura or pericardium Macroscopic invasion into surrounding fatty tissue or grossly adherent to, but not through, mediastinal pleura or pericardium Without invasion of great vessels Without invasion of great vessels With invasion of vessels With invasion of vessels Pleural or pericardial dissemination Pleural or pericardial dissemination Lymphatic or hematogenous metastasis Lymphatic or hematogenous metastasis In more than 90% of TAMG cases, both the MG and thymoma diagnoses are made concurrently, and optimal management requires adequately addressing both conditions [11]. In this review we will discuss the clinical presentation and diagnosis of TAMG, with an emphasis on features that are mostly unique to TAMG. Special considerations for the treatment of MG in the context of thymoma as well as the treatment of thymoma and prognosis will also be covered. Clinical Presentations Presentation to Neurologist TAMG Myasthenia gravis accounts for the majority of autoimmune disorders associated with thymoma, and by virtue of this, TAMG is a diagnosis frequently made by a neurologist [1, 15]. The average age of patients with TAMG is 50–55 years and there does not seem to be a significant male to female predilection [3, 5, 6, 7, 12, 16, 17, 18]. TAMG presents more commonly with Masaoka–Koga stage I to II thymoma, and the presence of metastasis at the initial diagnosis is unusual [5]. Almost all (99%–100%) TAMG patients are seropositive for AChR antibodies, and antibody titers tend to be higher in TAMG when compared to non‐thymomatous MG (NTMG), with some studies demonstrating average AChR binding antibodies titers exceeding 50 nmol/L in TAMG [11, 12, 13, 19, 20]. Table 3 lists a comparison of clinical and laboratory features between TAMG and AChR antibody positive NTMG [21, 22, 23, 24, 25, 26]. Patients with TAMG are more likely to manifest as generalized MG [18, 20, 27]. At presentation approximately 70% of TAMG patients have generalized disease, with Myasthenia Gravis Foundation of America (MGFA) classes II and III being the most common [6, 7, 28, 29]. For those TAMG patients presenting initially with a purely ocular phenotype, almost all will evolve and develop generalized symptoms at maximal disease severity [16, 27]. Patients with TAMG also appear to be at higher risk for myasthenic crisis compared to those with NTMG [20, 30]. Notably, the frequency of post‐operative myasthenic crisis (POMC) is higher for TAMG patients than NTMG patients undergoing thymectomy, suggesting that non‐surgical factors (e.g., disease severity) may be significant contributors to the event [31, 32]. TABLE 3Clinical features of AChR antibody positive myasthenic patients with and without thymoma.TAMGThymoma negativeAge (years) at MG diagnosisAverage 50EOMG (age < 50)LOMG (age ≥ 50)Thymic HistologyThymoma B2 > B1 > B3 > AB > A Normal: 20% FH: 80% Normal: Rare FH: Rare Atrophy: > 90% Sex (male vs. female)1:11:32:1Maximal disease severityOcular< 10%10%–15%30%Mild generalized30%30%25%–30%Severe generalized40%35%25%–30%Myasthenic crisis20%10%–15%10%Other associated antibodiesTitin60%–70%< 10%50%–60%Ryanodine receptor60%–70%Rare10%–15%IL12, INFα75%Rare30%Long‐term treatment outcomesComplete stable remission10%–35%25%10%Improved75%65%–75%80%–90%Unchanged/worse< 10%< 10%< 10%Abbreviations: EOMG = early onset myasthenia gravis; FH = follicular hyperplasia; LOMG = late onset myasthenia gravis; MG = myasthenia gravis; TAMG = thymoma associated myasthenia gravis. Clinical features of AChR antibody positive myasthenic patients with and without thymoma. Normal: 20% FH: 80% Normal: Rare FH: Rare Atrophy: > 90% Abbreviations: EOMG = early onset myasthenia gravis; FH = follicular hyperplasia; LOMG = late onset myasthenia gravis; MG = myasthenia gravis; TAMG = thymoma associated myasthenia gravis. The molecular mechanisms underlying NTMG and TAMG appear different, which may explain their different clinical course. In early onset AChR antibody positive NTMG, lymphoid follicular hyperplasia, germinal center formation, and pathogenic involvement of medullary thymic epithelial cells and myoid cells are the hallmarks [33]. Late onset AChR antibody positive NTMG is typically associated with thymic involution and low regulatory T lymphocyte activity [34]. In TAMG, thymoma preferentially emerges from the thymic cortex region and lacks a functional medulla, where mature antigen‐presenting cells participate in the process of negative selection [35]. Thymic follicular hyperplasia and intra‐thymic myoid cells are not typical features of TAMG [36]. It has been reported that more than 95% of thymomas lack autoimmune regulator (AIRE) expression along with reduced major histocompatibility complex class II molecule expression, both of which are important in preventing the generation of autoreactive T lymphocytes [37]. Due to the high association of thymoma with MG, all MG patients at the time of diagnosis should be screened for the presence of thymoma. A particularly high‐risk group is the middle‐aged patients presenting with generalized MG and moderate to high AChR titers. Thymoma With Asymptomatic AChR Antibody Positivity Up to one third of patients with thymoma are seropositive for AChR antibodies but lack clinical manifestations of MG. Antibody titers in these individuals typically decrease but persist after thymectomy [6, 38, 39]. A positive AChR antibody result in any patients with thymoma necessitates a careful review and examination for MG‐specific signs or symptoms. At times, there may be additional need for electrodiagnostic testing. The majority of seropositive thymomatous patients without preoperative MG will never develop MG following thymoma removal; however, positive AChR antibody in the pre‐operative period may be associated with an increased risk of developing post‐operative MG [6, 38, 39, 40, 41]. Thymoma With Other Neuromuscular Manifestations Several other autoimmune neuromuscular conditions can be seen in patients with thymoma, in isolation or coexistence with MG. The syndrome of neuromyotonia (NMT) is the next most common neuromuscular disorder associated with thymoma, and approximately 20% of patients with NMT have a thymoma [1, 11, 42]. The majority of patients with thymoma associated NMT also have a concomitant MG diagnosis [42, 43]. Less common paraneoplastic neurologic manifestations of thymoma include Morvan syndrome, myositis, autonomic neuropathy, or stiff‐person syndrome [11, 42, 43, 44, 45, 46]. Paraneoplastic myositis can also occur in association with thymoma with or without MG and present with both proximal and distal weakness as well as distal muscle contractures [45, 47, 48]. The presence of these multiple overlapping neurological conditions could make a diagnosis of TAMG challenging. Presentation to Non‐Neurologist Other than neurologists, patients with thymoma may present initially to internists, pulmonary medicine specialists, ophthalmologists, but more commonly to thoracic surgeons and oncologists. Their presentation to the thoracic surgeons or oncologists can be in several different ways: (1) asymptomatic patients with incidental finding on chest imaging suggestive of a thymoma; (2) mediastinal mass with associated symptoms secondary to local compression such as chest discomfort, coughing, dyspnea, or in severe cases, symptoms of dysphagia, phrenic nerve paralysis, or superior vena cava syndrome; (3) non‐neurological paraneoplastic syndromes in the setting of a mediastinal mass. Historically, the breakdown of such presentations has been roughly one third for each [49, 50]. Given the proliferation of axial imaging, the percentage of patients with asymptomatic tumors is likely rising. When facing an incidental anterior mediastinal mass, differential diagnoses often include thymoma, thymic cyst, thymic hyperplasia, lymphoma, germ cell tumor or thyroid goiter. Type B symptoms (i.e., fever, night sweat, weight loss, and fatigue) and palpable lymphadenopathy would suggest lymphoma. Laboratory evaluation should include testing of AChR antibody, alfa fetoprotein, beta human chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) [51]. Elevation of beta‐HCG and alpha fetoprotein are virtually diagnostic of non‐seminomatous germ cell tumor, and elevated LDH raises the possibility of lymphoma. Evaluation is largely the same for patients presenting with local compressive symptoms. Referral to an oncologist is typically indicated for individuals who present with several other paraneoplastic syndromes (e.g., pure red cell aplasia, immunodeficiency) and/or advanced stages of thymoma, in whom perioperative systemic therapy may be indicated. Pure red cell aplasia and hypogammaglobulinemia occurs in approximately in 6%–8% of patients with thymoma [1, 11]. At times, these disorders coexist with MG. Epidemiological Trends in TAMG Thymoma is a relatively rare neoplasm comprising less than 2% of all malignancies, with a yearly incidence rate of 1.3 cases per million people [9, 50, 52]. Black, South Asian, and Pacific Islanders appear to have higher incidences of thymoma compared to white individuals [53]. Thymomas are uncommon in children and adolescents. As mentioned previously, the pooled estimate of paraneoplastic MG associated with a thymoma is roughly 15% to 20% of all MG patients, but there are significant regional differences. Studies in Asia demonstrate that the incidence of thymoma in MG approaches 30% [4]. Thymoma is uncommon in very late onset MG, defined as presentation after 65 years of age. It has been demonstrated that the MG prevalence rate is gradually increasing, especially in individuals 65 years of age and older [54, 55, 56]. As the proportion of elderly MG patients increases over time, we are likely to see a decreased portion of TAMG among all MG patients. Indeed, in a modern cohort, the incidence of thymoma in MG patients was only 5% [26, 57]. Laboratory Findings in TAMG Nearly all patients with TAMG are seropositive for AChR antibodies [12, 19]. There are rare case reports of TAMG patients with positive muscle specific kinase and lipoprotein receptor‐related protein 4 antibodies or being seronegative, but these are likely a clustering of stochastic events [58, 59]. All patients with MG warrant imaging studies to exclude the presence of thymoma, regardless of serological status. Antibodies to other muscle specific antigens including titin and ryanodine receptor (RyR), termed striational antibodies, are also present in roughly 60%–70% and 40%–70% of all TAMG patients, respectively [16, 22, 60, 61]. Striational antibodies are present in approximately half of all patients with late onset MG without thymoma, and can be seen in many other non‐myasthenic autoimmune conditions [61, 62]. Given the non‐specific nature of striational antibodies, they should not be used as unequivocal evidence to secure a diagnosis of MG or thymoma. Even when considering the diagnosis of thymoma alone, the positive predictive value of isolated positive striational antibodies is only 7% for the presence of thymoma, but increases to 23% with titers exceeding 1:61,440 [62]. In patients with early onset (≤ 50 years of age) MG, striational antibodies are rarely detected outside TAMG. Therefore, in this population, testing for a high titer of striational antibodies may provide some diagnostic value for thymoma, especially in patients who do not have classic radiological findings [22, 61, 62]. Patients with MG and positive RyR antibodies are more likely to present with neck flexion and bulbar weakness, and this may in part explain the more severe myasthenic phenotype in TAMG [63]. The other group of antibodies detected in TAMG are those directed against cytokines including interferon alpha and interleukin 12 (Table 3). These antibodies are more commonly seen in TAMG compared to both late and early onset NTMG. The clinical significance of these antibodies is unclear, but a rise in their concentration in TAMG patients may signal thymoma recurrence [22]. At present, the usefulness of anti‐cytokine antibody testing in TAMG is mostly restricted to research purposes due to limited availability and the further need for verification of its clinical utility. Radiographic Diagnosis of Thymoma Diagnostic Workup of a Thymic Mass A significant portion of thymoma, especially when large, can be identified on routine chest radiograph [64]. When there is a clinical suspicion of thymoma, contrast‐enhanced CT is usually the imaging modality of choice. Use of contrast is not mandatory to identify and characterize a thymic mass, but it is valuable in assessing the tumor invasiveness and detecting small pleural and pericardial implants (Figure 1). Omission of contrast will likely limit the diagnostic yield and negatively influence management guidance [65, 66]. Axial CT images of the chest in soft tissue windows demonstrate: (A) Non‐contrast image with normal appearing thymus with fluffy, triangular shaped soft tissue density and interspersed fat (arrows), (B) contrast enhanced image with a triangular shaped soft tissue density mass (arrowheads) proven to be thymic hyperplasia, (C) contrast enhanced image with a round fluid density mass that demonstrates minimal peripheral calcification (bent arrow) consistent with a thymic cyst, (D) contrast enhanced image with a homogenous soft tissue density mass in the anterior mediastinum (dotted arrow), consistent with a low‐grade thymoma, (E) contrast enhanced image with drop metastasis in the right lower pleural space (thick arrow) in a patient with invasive thymoma, and (F) contrast enhanced image with a heterogeneously enhancing mass in the anterior mediastinum with central necrosis, invasion and erosive changes of the adjacent sternum and rib (curved arrow), proven to be a thymic carcinoma. On chest CT, the normal adult thymus presents as triangular soft tissue in the anterior mediastinum and demonstrates variability in size and shape (Figure 1). Low‐risk forms of thymoma (WHO A, AB, B1 subtypes) appear oval or round, smooth and uniform on CT scan with mild to moderate homogenous contrast enhancement. These are rarely invasive, although as they enlarge with time, they may bleed or turn necrotic. High‐risk types (WHO B2 and B3) show features including cystic changes, calcification, and possible invasion and spread [67, 68, 69]. When evaluating thymoma with CT imaging, the presence of pleural “drop” metastases strongly indicates a metastatic thymoma, although other signs may include pleural thickening, vessel encasement, and irregular lung borders [70, 71, 72]. Thymic carcinomas are large, aggressive, and irregular lesions that often invade the nearby structures (Figure 1). However, imaging findings alone cannot reliably distinguish tumor types. Unlike other mediastinal tumors, lymphadenopathy or distant metastasis is seen in less than 5% of thymoma cases [73]. When lymph nodes are involved in thymoma, they are mainly localized in the anterior mediastinum in > 90% of cases [74, 75, 76]. Magnetic resonance imaging evaluation of an anterior mediastinal mass can be complementary to CT under various circumstances. MRI plays a major role in the evaluation of thymoma in patients with iodine allergy or renal failure. Low‐risk thymomas typically show intermediate T1 signal, T2 heterogeneity, and variable enhancement, while high‐risk lesions appear more aggressive and heterogeneous (Figure 2) [71]. PET imaging with [18F]‐fluorodeoxyglucose (FDG‐PET) together with CT may help to identify nodal or distant metastases, thus providing more accurate staging of thymoma and guidance in treatment planning [76]. A lesion with increased FDG uptake and high standard uptake value (SUV) measurements suggests aggressive disease (Figure 3). However, thymoma can be FDG‐PET negative, thus absence of FDG activity in a thymic mass does not rule out a malignant thymoma [64]. Although a high degree of FDG uptake often suggests aggression, low‐grade thymic tumors, thymic hyperplasia, and normal thymus may also show increased uptake. SUV thresholds have been proposed, but lack universal acceptance [69]. MR imaging of the chest in a patient with a low grade thymoma shows: (A) fluid sensitive STIR image with high signal (arrow), (B) pre contrast T1 weighted image (white arrowhead) and (C) post contrast T1 weighted image showing variable enhancement (black arrowhead), and (D) diffusion weighted image with minimal increased signal indicating cellularity within the mass (dotted arrow). MR imaging of the chest in another patient with anterior mediastinal soft tissue density demonstrates intermediate signal (bent arrow) on in phase imaging (E) and drop out of signal (curved arrow) on out of phase imaging sequences (F) indicating thymic hyperplasia. Axial fusion PET‐CT image shows an FDG avid lesion in (A) the left anterior mediastinum (arrow) and (B) drop metastasis in the left retrocrural (broken arrow) and left pleural/intercostal (arrowhead) spaces. This lesion turned out to be a high grade malignant thymoma. Common Differential Diagnoses of Anterior Mediastinal Mass Thymic hyperplasia, whether true or lymphoid type, can mimic thymic tumors. True hyperplasia is a simple enlargement of the thymus. Lymphoid hyperplasia, which is often linked to MG, shows lymphoid follicle growth. On CT, thymic hyperplasia is located at the midline with a bipyramidal shape often intercalated with fat (Table 4). In a portion of cases, CT may not accurately differentiate thymoma from thymic hyperplasia, and unnecessary thymectomy may be carried out based on CT results alone [77]. On the other hand, MRI can help distinguish thymic hyperplasia from thymoma. Fat‐saturated and opposed‐phase images show signal loss in hyperplasia but not in thymoma (Figure 2, Table 4). Thymomas typically demonstrate restricted diffusion on diffusion weighted imaging, reflecting tumor cellularity, whereas the normal adult thymus does not. Pediatric thymus may still restrict diffusion due to its naturally high cellularity [78, 79, 80, 81]. TABLE 4Radiological features of common thymic pathologies.DisorderCTMRIPETThymic hyperplasiaDiffuse symmetric enlargement T1/T2: intermediate signal, no enhancement In‐phase and opposed‐phase: loss of signal Minimal physiologic uptakeThymoma Low‐risk types: oval or round, smooth and uniform with mild to moderate homogenous contrast enhancement; may bleed or turn necrotic High‐risk types: cystic changes, calcification, possible invasion and spread. Pleural “drop” metastases, pleural thickening, vessel encasement, and irregular lung borders all indicate malignant thymoma T1: isointense to muscle, with linear enhancement representing fibrous septa T2: heterogeneous signal, possible cystic areas, fibrous septa of low signal In‐phase and opposed‐phase images showing no loss of signal High‐grade thymoma and thymic carcinoma showing higher FDG uptake than the othersThymic cystWell‐circumscribed, fluid density, unilocular or multilocular with well‐defined walls, may have increased density if hemorrhage or infection occurs T1: low signal without enhancement T2: High signal When hemorrhagic or infected, may have high signal on T1 and T2 No uptakeThymolipomaMay be lobulated, with mixed fat and soft tissue density or almost entirely fatty T1: high fat signal with thymic soft tissue showing intermediate signal and possible enhancement STIR/fat saturation: suppression consistent with fat Typically no uptake, thymic tissue may show slight uptakeGerm cell tumorsMature and immature teratomas appear as well‐defined lobulated cystic masses, with fatty foci, fat‐fluid levels, and rim like or toothlike calcification T1: high signal fat T2: high signal fat Fat saturation: low signal May have minimal FDG uptake; high activity may indicate malignant componentsLymphomaSmooth or lobulated soft tissue mass of rapid growth conforming to surrounding structures rather than displacement or invasion, may contain small cystic areas and calcification after treatment T1: hypointense/isointense signal to muscle with diffuse enhancement T2: typically hyperintense but variable, hypointense after treatment High FDG uptake that decreases after treatmentAbbreviation: FDG; fluorine 18 fluorodeoxyglucose. Radiological features of common thymic pathologies. T1/T2: intermediate signal, no enhancement In‐phase and opposed‐phase: loss of signal Low‐risk types: oval or round, smooth and uniform with mild to moderate homogenous contrast enhancement; may bleed or turn necrotic High‐risk types: cystic changes, calcification, possible invasion and spread. Pleural “drop” metastases, pleural thickening, vessel encasement, and irregular lung borders all indicate malignant thymoma T1: isointense to muscle, with linear enhancement representing fibrous septa T2: heterogeneous signal, possible cystic areas, fibrous septa of low signal In‐phase and opposed‐phase images showing no loss of signal T1: low signal without enhancement T2: High signal When hemorrhagic or infected, may have high signal on T1 and T2 T1: high fat signal with thymic soft tissue showing intermediate signal and possible enhancement STIR/fat saturation: suppression consistent with fat T1: high signal fat T2: high signal fat Fat saturation: low signal T1: hypointense/isointense signal to muscle with diffuse enhancement T2: typically hyperintense but variable, hypointense after treatment Abbreviation: FDG; fluorine 18 fluorodeoxyglucose. Thymic cysts, simple or complex, are usually incidental, fluid‐filled, and lack solid parts (Figure 1). They may be congenital (unilocular, rare) or acquired (multiloculated, post‐surgery, infection, or tumor‐related). Careful distinction from cystic tumors, including cystic thymomas, or other mediastinal cysts is essential [82]. Thymic cysts are shown as non‐enhancing T2‐bright, T1‐dark lesions on MRI. MRI can often distinguish a thymic cyst from a cystic thymoma, as the latter often has fibrous septa and/or mural nodules which are not well appreciated on CT (Table 4) [64]. Thymolipoma represents about 5% of thymic tumors, and it presents as a fatty, encapsulated mass compressing but not invading nearby structures. Germ cell tumors (15%–25% of anterior mediastinal masses) include teratomas, seminomas, and more rare aggressive non‐seminomatous types. Teratomas, mature or immature, may show cystic spaces, fat, and calcifications; immature forms are more solid. Complications include rupture, hemorrhage, or rarely, fistula to nearby structures [72, 74]. Lymphoma presents as 10%–20% of mediastinal masses, usually as part of systemic disease. Primary mediastinal lymphoma cases are less common [83]. Imaging shows a bulky, uniform soft‐tissue mass often with a rapid expansion that may compress airways or the superior vena cava, frequently associated with cystic change, pleural or pericardial effusion, and characteristic MRI enhancement patterns (Table 4) [83, 84]. Transthoracic Needle Biopsy Versus Surgical Resection Percutaneous biopsy of an anterior mediastinal mass is indicated if the history and physical, serologic testing, and imaging findings do not provide a definitive diagnosis. The most common indications would be a suspicion of invasive thymic malignancy that would require induction therapy prior to resection. Percutaneous needle biopsies can prevent unnecessary surgical biopsies, which have a higher risk of tumor dissemination. Percutaneous needle biopsy, however, is not always necessary for a newly discovered anterior mediastinal mass. A well‐circumscribed, solid mass in the anterior mediastinum in a patient with seropositive MG may proceed directly to the operating room without the need for biopsy due to the high probability of a thymoma. For small lesions, percutaneous biopsy may not be possible due to proximity to the heart and great vessels; thus, surgical excision is an appropriate next step in patients with appropriate risk profiles [85, 86, 87]. Treatment Considerations in TAMG Neuromuscular Treatment Immunotherapy for TAMG As TAMG is usually generalized, treatment with immunotherapy for longer than 1 year is indicated in more than 90% of patients [88]. Acetylcholinesterase inhibitors and corticosteroids are fast‐acting medications that are effective in more than two‐thirds of TAMG patients [89, 90]. TAMG patients being treated pre‐operatively with corticosteroids are more likely to achieve complete stable remission at 3, 5, and 10 years [89]. In addition to improving myasthenic symptoms prior to thymectomy, corticosteroid usage reduces the size of thymoma in some patients, which may allow an easier surgical resection, although the frequency of this beneficial effect is not clear [91, 92]. Given that many patients with TAMG require long term treatment, non‐steroidal immunosuppressive agents including azathioprine, mycophenolate mofetil, and methotrexate are often employed. However, all these agents have a long latency to effect and should be preferentially considered for long‐term maintenance therapy. Of particular interest is the use of tacrolimus which may have a faster onset of action [93]. As noted previously, TAMG patients commonly harbor RyR antibodies; RyR antibodies inhibit calcium release from the sarcoplasmic reticulum and affect excitation‐contraction coupling and so are likely to have some pathophysiological significance in MG [16, 22, 60, 61, 94]. In addition to its immunosuppressive effects, tacrolimus enhances RyR‐related calcium release and has been shown to be beneficial in small unblinded studies in patients with TAMG [95, 96, 97]. Tacrolimus may be a very reasonable first choice if a non‐steroidal immunosuppressive medication is desired for TAMG, based on its mechanisms of action. Over the last decade, many newer therapies (complement inhibitors, neonatal Fc receptor antagonists, and B cell depletion therapy) for MG have been developed at a rapid pace. However, patients with active thymoma were excluded in almost all pivotal interventional trials employing these newer therapies [98, 99, 100, 101]. Limited data on the efficacy of these newer generation therapies seem to suggest a therapeutic value. For patients with severe or refractory myasthenic symptoms, complement inhibitors have been used in TAMG both in the pre‐ and post‐thymectomy periods. The response to these therapies appears to be comparable to that in NTMG [102, 103, 104]. In an unblinded study, 40 generalized TAMG patients received two cycles of efgartigimod prior to thymectomy and two additional cycles after surgery. There was improvement in MG specific outcome scores with this treatment [105]. As almost all TAMG are AChR antibody positive, our recommendation remains that when considering the newer generation therapies, patients with TAMG should be treated similarly to AChR antibody positive NTMG. Combined Usage of Chemotherapy and Immunotherapy Chemotherapies are indicated for patients with advanced stage thymoma (Section 6.3). The immunosuppressive effects of various chemotherapies may help alleviate myasthenic symptoms in TAMG. It has been reported that TAMG patients who previously failed traditional treatments including intravenous immunoglobulin (IVIG), plasmapheresis, and corticosteroids may show improvement in myasthenic symptoms after starting chemotherapy for thymoma, with a corresponding drop in the AChR antibody titer [106]. However, concomitant use of chemotherapy and immunosuppressive treatments poses an increased risk of infections and other complications. TAMG patients who are starting chemotherapy should have other immunosuppressive treatments reduced quickly to the lowest possible intensity following the improvement of myasthenic symptoms. Many chemotherapeutic agents for thymoma are myeloablative. It is therefore best to avoid concomitant use of non‐steroidal immunosuppressive treatments and chemotherapeutic agents, as both may cause cytopenia. While TAMG patients receive intensive chemotherapeutic therapy, prednisone would be preferred over a non‐steroidal immunosuppressive agent as it is commonly utilized in conjunction with traditional chemotherapy and may itself have some effect on the size of the thymoma as noted previously [91, 92]. The dose of prednisone should be kept as low as possible without sacrificing control of myasthenic symptoms, and coordination with the treating oncologist is advisable. Surgical Treatment of Thymoma Surgical Approaches When a MG patient presents with typical radiological features of a thymoma, surgery is usually indicated without the need for a biopsy. The goals of surgical therapy for a myasthenic patient presenting with thymoma are: (1) R0 resection of the thymic malignancy, defined as a complete removal of the thymoma with no visible or microscopic residual tumor; and (2) complete removal of the thymus. Complete surgical resection of both thymoma and thymus ensures optimal long‐term oncological outcome and myasthenic control and should be considered for both TAMG patients and thymomatous patients with positive AChR antibodies. Traditional sternotomy was performed in the landmark study firmly establishing the role of thymectomy for the management of non‐thymomatous MG [107]. The utilization of minimally invasive techniques, either VATS (video‐assisted thoracoscopic surgery) or robotic surgery, is rapidly increasing for the management of non‐thymomatous MG and early‐stage (Masaoka–Koga stage I or II) thymoma [108, 109, 110]. It is now generally accepted that minimally invasive surgery can be safely performed for TAMG patients with early‐stage thymoma. This has been associated with reduced blood loss, less postoperative complication and reduced length of stay [111]. Moreover, there has been no compromise in oncologic results with the use of minimally invasive techniques [108, 109, 110]. For larger tumors and tumors with possible invasion of adjacent structures, a minimally invasive approach may still be appropriate, provided that the surgeon has counseled the patient regarding the possibility of intraoperative switching to sternotomy [112]. Sternotomy remains an important tool to ensure a safe and effective operation, and patients should be informed that a sternotomy is a possibility with any thymic surgery for the purpose of defining anatomy, controlling bleeding, performing vascular resection and reconstruction, and enhancing intraoperative visibility. Minimally invasive approaches include various unilateral, bilateral, and subcostal techniques. At present, no single technique has demonstrated superiority; thus, choice of approach is largely a matter of the surgeon's experience and available resources. Robotic thymectomy provides a high‐resolution three‐dimensional view and improved dexterity of tremor‐free instruments, allowing a safe dissection around vulnerable nerves and great vessels. However, it is associated with high cost [29]. Transcervical thymectomy is waning in popularity due to concerns regarding the completeness of resection and the emergence of other minimally invasive techniques which provide much better visualization of the mediastinum. Both benign thymic masses including cysts and thymolipomas as well as more malignant anterior mediastinal tumors have been reported to be in association with MG [113, 114, 115, 116]. Given the relative rarity, it remains unclear whether these non‐thymomatous masses are truly causing MG or simply represent a coexisting process. Unfortunately, the differentiation of a thymic cyst from a cystic thymoma or a thymolipoma from a thymoma based on clinical and radiological features may not be reliable. Our recommendation remains that all mediastinal masses in myasthenic patients should be considered for resection to exclude malignancy, provided that the patient is an appropriate candidate for surgery. When comparing MG patients undergoing extended thymectomy, those with thymolipomas have similar long‐term outcomes as NTMG patients [113, 116]. Preoperative MG Optimization and Avoidance of Perioperative Myasthenic Exacerbation As mentioned previously, all thymomas are malignant thus the identification of a thymoma warrants elective surgical resection to be performed when the patient is deemed an appropriate candidate for surgery. Ideally, candidate patients for thymectomy should be hemodynamically stable, able to tolerate general anesthesia, and without significant signs of coagulopathy. Myasthenic symptoms in TAMG patients should be stabilized or controlled prior to elective thymectomy. TAMG patients with minor myasthenic symptoms could go through thymectomy even if they are not on any immunotherapy for MG. Conversely, there is no indication for acute surgical intervention for thymomatous patients in myasthenic crisis. Patients in crisis should be medically stabilized and thymoma should be treated in an elective fashion once their myasthenic symptom control is optimized. One of the most feared complications for any MG patients to undergo thymectomy is the development of POMC, which occurs in 4%–30% of patients [117, 118, 119, 120]. Certain clinical characteristics increase the risk of POMC including history of prior myasthenic crisis, bulbar symptoms, low vital capacity, high AChR antibody titer and abnormal facial nerve repetitive nerve stimulation [121, 122, 123, 124, 125]. More invasive surgeries (e.g., trans‐sternal versus video‐assisted thoracoscopic thymectomy), longer operative time, and higher amount of intra‐operative blood loss as well as post‐operative pneumonia also carries a higher risk for POMC [117, 121, 126, 127]. Both preoperative IVIG and plasmapheresis have been utilized to reduce risk for POMC [128, 129]. However, not all patients need additional pre‐operative treatment. It has been demonstrated that the risk of POMC is very low in well controlled MG where quantitative myasthenia gravis score is less than 8 (which would be approximately equal to MG‐activity of daily living score of 5) and vital capacity is > 70% of the predicted normal value or two liters [130]. In patients who are at high risk for POMC, we recommend IVIG at 2.0 g per kilogram of body weight over 2–3 days, or three sessions of plasma exchange with the last session occurring at least 48 h prior to surgery to allow for adequate repletion of coagulation factors and stabilization of any fluid shifts that occur. The preoperative usage of corticosteroids and non‐steroidal immunosuppressive treatments may have implications on peri‐operative complications. Patients on high dose prednisone (defined as > 1 mg/kg/day) at the time of surgery do appear to have higher rates of complications including infections and poor wound healing. Prednisone doses of less than 1 mg/kg/day, however, seem to have either a protective effect or no effect on surgical morbidity [89, 90, 131]. Corticosteroids therefore can be safely utilized preoperatively for myasthenic symptom control. Ideally, prednisone dose should be tapered prior to surgery as low as possible without sacrificing myasthenic symptom control. In our institution, we prefer to reduce prednisone daily dosage to be ≤ 30 mg per day prior to thymectomy. Non‐steroidal immunosuppressive agents such as azathioprine or mycophenolate mofetil have a long duration of action; therefore, discontinuing these medications pre‐operatively and restarting post‐operatively is of little benefit. While not studied specifically in a TAMG population, the added surgical risk of these agents is minimal [132, 133]. Acetylcholinesterase inhibitors can be safely continued perioperatively. For postoperative patients who are temporarily unable to take oral medications, parenteral corticosteroids and acetylcholinesterase inhibitors could be administered, and non‐steroidal immunosuppressive agents can be held for a few days without deleterious consequences. When considering the preoperative optimization of therapy for TAMG, consideration must be made regarding the interplay of medical stability and surgical risk. Direct communication and care coordination between the neurologist and the surgeon are essential to ensure a good perioperative outcome. Anesthesia is required for TAMG patients who undergo thymoma removal. Depolarizing neuromuscular blocking agents (such as succinylcholine) should be avoided. Non‐depolarizing neuromuscular blocking agents (e.g., rocuronium) should be used with caution, and the coadministration of sugammadex has significantly reduced the incidence of postoperative myasthenic crisis [134]. Intravenous magnesium should be avoided due to its depressing action at the neuromuscular junction. Benzodiazepines and opiates inhibit respiratory function, and their usage should be carefully monitored. Other Complications of Thymectomy Thymectomy is a safe and effective operation when performed by experienced surgeons. A recent review of robotic thymectomies documents an intraoperative complication rate of 0%–4% with a conversion rate to sternotomy of 0% to 8.9% [120]. Interestingly, a meta‐analysis comparing robotic to VATS thymectomy did demonstrate a lower conversion rate in robotic cases, but no difference in oncologic outcomes [135]. The presence of MG, notably, does increase the risk of postoperative events [118]. Injuries to the great vessels, pericardium and lung parenchyma, and cardiac arrhythmia are rare but serious complications [136]. Phrenic nerve injury is another feared complication of thymectomy, as the phrenic nerves form the lateral boundaries of the dissection. Optimal phrenic visualization is why some surgeons prefer a bilateral approach rather than a unilateral approach for thymectomy. At times, unilateral phrenic nerve resection may be necessary to permit appropriate tumor resection and achieve acceptable oncologic results. Careful visualization of the nerves and avoidance of cautery/traction‐related injuries is essential. Special Consideration: Evaluation and Management of Post‐Treatment Dyspnea in TAMG The evaluation of dyspnea in TAMG patients, especially in those who have received thymectomy, radiation, or both, is complicated. Potential causes of dyspnea in this context are manifold and may include respiratory muscle weakness from MG, radiation pneumonitis, postoperative causes such as chest wall restriction due to pain and postoperative mechanistic change, injury to lung parenchyma or great vessels, phrenic nerve palsy, atelectasis, pneumonia, volume overload, or pulmonary embolism. Starting or intensifying immunotherapy to treat dyspnea may have no effect or could even exacerbate non‐MG related etiologies. Respiratory muscle weakness due to MG is usually accompanied by other myasthenic features such as oculo‐bulbar, neck flexion or proximal limb muscle weakness. Hypercapnia is typical of respiratory failure in MG so hypoxia in the absence of significant hypercapnia should warrant evaluation for non‐myasthenic etiologies [137, 138]. Pulmonary function tests may not accurately differentiate MG from other etiologies that cause a restrictive pattern such as radiation pneumonitis [139]. Similarly, weak inspiratory force cannot be used in isolation to determine the presence of respiratory muscle weakness caused by MG as patients with post‐operative pain or surgical lung resection could have similar findings. A more specific finding for MG would be a drop in vital capacity by more than 20%–30% with supine positioning which indicates bilateral diaphragmatic muscle weakness, although phrenic nerve palsies associated with thymoma or surgery will demonstrate similar findings [138]. Chest radiographs revealing asymmetric diaphragm elevation and fluoroscopic evaluation of diaphragm function, a sniff test, and diaphragmatic ultrasound are useful tools for identifying phrenic nerve pathologies. In summary, differentiating the various causes of dyspnea in TAMG patients who have received surgery or radiation can be difficult and no one clinical factor or test can be solely relied upon to differentiate MG from non‐MG causes. Overlapping diagnoses may be present so a cursory evaluation for other etiologies should be performed before embarking on or intensification of MG specific treatments. Long Term Risks of Thymectomy Outside TAMG Kooshesh et al. published a retrospective case–control study analyzing long term outcomes in 1420 patients who underwent thymectomy compared to matched controls who underwent cardiac surgeries. In their study, risks of cancer, all‐cause mortality, and autoimmune diseases were higher in the thymectomy group [140]. In their study, the most common indication in the study for thymectomy was resection of a thymic neoplasm. However, the surgical mortality for cancer surgery may not be equivalent to non‐cancer related cardiac procedures. As noted by Kaminski and colleagues, analysis of survival curves between the thymectomy and the matched control groups in the Kooshesh et al. study revealed an immediate separation of the thymectomy and the control groups in the first year followed by relatively similar mortality trends for the remainder of the study. This observation raises some questions about the matching of groups and suggests a possible difference in surgical mortality between the thymectomy and the control groups [140, 141]. As we have discussed previously, thymoma is linked to the development of numerous autoimmune diseases, some of which may occur post thymectomy. Therefore, the elevated risk of autoimmune diseases in a thymectomy population is more likely related to the presence of thymoma, rather than the effects of the thymectomy. Several other studies have not demonstrated an increased cancer risk in patients who had undergone thymectomy [142, 143, 144]. When taken together, there are no consensus results indicating long‐term adverse health outcomes following thymectomy. Thymectomy is an accepted treatment for thymoma and remains a safe and efficacious treatment for non‐thymomatous generalized MG with positive AChR antibodies. Oncological Treatment Perioperative Radiation Treatment and Chemotherapy With the lack of randomized clinical trials comparing multimodality approaches for the treatment of thymomas, current clinical guidelines on the use of radiation and chemotherapy are mostly derived from observational studies. A formal, multidisciplinary evaluation should be conducted to optimize the management strategy for each individual TAMG case. The consideration for postoperative radiotherapy is largely dependent on tumor stage. In addition, histological features from the surgical pathology specimen guide decisions on adjuvant treatment. Patients with Masaoka–Koga stage I thymoma should be offered surveillance without adjuvant therapy. However, postoperative radiotherapy should be provided to those with stage I disease with high‐risk pathological features (e.g., WHO subtype B2/B3, tumor necrosis, high mitotic activity, nuclear atypia, adjacent organ/vessel invasion, incomplete surgical margins), as well as Masaoka–Koga stage II and III thymomas regardless of histological features. The addition of radiation therapy after thymectomy does not seem to improve overall survival in patients with Masaoka–Koga stage I thymoma who achieved a complete resection and lack poor prognostic features on pathology [145, 146, 147]. However, analyses of postoperative radiotherapy for thymic tumors using multiple large database demonstrated improved overall survival and decreased risk of recurrence in patients with Masaoka–Koga stage II and III thymoma, in addition to those with positive surgical margins or macroscopic residual disease after resection [147, 148]. Current data suggests that postoperative radiotherapy improves overall survival at both 5 years (95% vs. 90%) and 10 years (86% vs. 79%), and is therefore recommended for these patient subgroups [149]. Outside of the metastatic setting, chemotherapy is typically reserved for patients with locally advanced, borderline resectable disease. Borderline resectable thymoma is defined as tumor invasion into at least one of the following four adjacent structures: (1) innominate vein; (2) phrenic nerve; (3) heart; and (4) great vessels [150]. If effective, preoperative chemotherapy reduces tumor burden, which may render an inoperable thymoma operable and potentially offers an improvement in overall survival. A retrospective analysis controlled for confounding factors by propensity score matching demonstrated improved overall survival with preoperative chemotherapy in patients with Masaoka–Koga stage III or IV thymic epithelial tumors, achieving a median overall survival of 103 months compared to 80 months in those who did not receive induction therapy [151]. For patients with borderline resectable thymoma, national guidelines recommend preoperative systemic therapy with a combination of cyclophosphamide, doxorubicin, and cisplatin. This recommendation is extrapolated from an intergroup trial that demonstrated relatively high response rates, prolonged survival, and a tolerable safety profile in patients with advanced thymoma [152]. Less commonly, carboplatin plus paclitaxel or cisplatin plus etoposide are given as induction therapy [153]. Role of Immune and Other Targeted Therapies Currently, there is no role for immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab, etc.) for the management of thymoma. These novel forms of treatment are historically associated with immune‐related adverse events, which are observed at exponentially higher rates in patients with advanced thymoma. For example, within a phase II trial evaluating the safety and efficacy of pembrolizumab for patients with advanced thymic epithelial tumors, five (71.4%) of the seven patients reported high‐grade (≥ grade 3) immune‐related adverse events including hepatitis, myocarditis, MG, colitis, and glomerulonephritis [154]. Ongoing research is focused on identifying biomarkers to better select patients who may benefit from immunotherapy. The relative lack of actionable mutations from comprehensive molecular profiling has led to the rare use of targeted therapies for thymoma [155]. However, multi‐kinase inhibitors (e.g., sunitinib, lenvatinib) demonstrate antineoplastic activity in thymic carcinomas and remain under investigation for advanced thymic epithelial tumors [156]. Other novel treatment regimens, such as antibody‐drug conjugates and immunomodulatory drugs, are in the early phases of clinical research and have yet to demonstrate efficacy in the management of thymoma [157]. Despite its rarity, the therapeutic landscape for thymoma continues to evolve. Prognosis of TAMG Influence of MG on Thymoma Outcomes The overall 5‐year survival of thymoma exceeds 90%, and about 55% when distant metastases occur [158]. Historically, the presence of MG was linked to worse survival outcomes for patients with thymoma, probably driven in large part by lack of available treatments for MG in the earlier years [159]. However, more recent cohorts indicate that the presence of MG does not negatively affect prognosis in patients with thymoma and may confer an improved survival at 5 and 10 years. Patients with TAMG are generally 10 years younger than those thymomatous patients without MG [3, 160]. The development of myasthenic symptoms probably leads to earlier screening, detection and treatment of thymoma [2, 3, 5, 6, 15, 28, 161]. Compared to thymoma patients without MG, TAMG patients present with thymoma of smaller sizes and earlier stages and less often a need for adjuvant chemotherapy and radiation [2, 6, 15, 161]. MG Outcome Following Thymoma Removal Despite a more severe disease phenotype and higher risk for myasthenic crisis at presentation, outcomes for patients with TAMG after thymectomy are generally quite good. Studies comparing short‐ and long‐term outcomes of TAMG to NTMG are heterogeneous, some reporting no differences in outcomes while others report lower rates of remission for TAMG [18, 20, 31, 162]. Following thymectomy, 75% of TAMG patients see improvement in myasthenic symptoms and complete stable remission is achieved in 10%–35% of individuals [7, 16, 28, 163, 164, 165]. Factors associated with worse MG outcomes post‐thymectomy include higher MGFA classification prior to thymectomy, higher thymoma tumor staging, B type histopathology, thymic carcinoma, and age over 55 years [7, 16, 28, 162, 163, 164, 165, 166]. Approximately 1%–11% of patients with no pre‐operative myasthenic symptoms may develop new onset MG postoperatively [3, 11, 16, 39, 40, 41, 167]. Median time to diagnosis of MG after thymectomy is 10–26 months but ranges from the immediately post‐operative period up to more than 20 years after thymectomy [3, 11, 16, 39, 40, 41]. An important risk factor for developing postoperative MG is the presence of preoperatively positive AChR antibody, and its higher pre‐operative titers correlate with further increased risk [167, 168, 169]. Thymoma patients who develop MG after thymectomy usually have an increase in their AChR antibody titer at MG diagnosis [168, 169]. It is likely that extra‐thymic lymphoid organs, such as bone marrow or lymph nodes, take over the production of autoreactive B cells following thymoma removal. Other risk factors associated with developing MG post‐thymectomy include female sex, type B tumor, and incomplete resection [3, 11, 16, 39, 40, 41, 167]. Thymoma Recurrence Risk Factors for Thymoma Recurrence Despite the often indolent behavior of thymoma, recurrence might occur in 5%–15% of cases [170]. The risk of thymoma recurrence depends on the tumor stage, size of the primary tumor, surgical resection status (i.e., R0 versus others), presence of high‐risk pathological features (see below), patient age and perioperative treatment approach [165, 171, 172, 173]. Of note, complete surgical resection (R0) is the most important prognostic factor for improved disease‐free survival in these patients [174, 175]. The likelihood of thymoma recurrence is extremely rare in patients with Masaoka–Koga stage I or II disease who achieve a complete resection at the time of surgery. Conversely, event‐free survival at 10 years is approximately 40%–60% in patients with Masaoka–Koga stage III or IV thymoma [172]. Certain pathological features such as WHO subtype B2/B3, tumor necrosis, high mitotic activity, nuclear atypia, adjacent organ/vessel invasion, and incomplete surgical margins confer a higher risk for thymoma recurrence and warrants consideration for postoperative radiotherapy with or without chemotherapy. In addition, tumor size appears to be an independent prognostic factor, in which tumors larger than 7.0 cm are associated with an increased risk of recurrence [172]. The copresence of MG does not appear to increase the risk of thymoma recurrence [3, 6, 161, 176]. Conversely, thymoma recurrence may have negative prognostic consequences for MG. At the time of thymoma recurrence, myasthenic symptoms may occur or worsen in roughly half of patients [11, 27, 39]. A thorough evaluation for thymoma recurrence should therefore be conducted in any post‐thymectomy patient with new onset MG or worsening control of myasthenic symptoms. However, not every case of myasthenic exacerbation requires repeated evaluation with chest imaging. Repeat imaging may not be necessary for those TAMG patients with clear triggers for myasthenic exacerbation or those with isolated easy‐to‐treat exacerbations. In this context, there is no clear association with thymoma recurrence and AChR antibody titers so a rising AChR antibody titer cannot be taken as unequivocal evidence of tumor recurrence [17]. Similarly, changes to titin antibody titer do not seem to precisely predict recurrent thymoma [22]. Monitoring for Thymoma Recurrence As with definitive management planning, surveillance for disease recurrence should follow a multidisciplinary approach. For patients with surgically resectable thymoma without need for adjuvant therapy, the treating surgeon/neurologist should continue to follow the patient under observation. Conversely, patients who receive radiation or chemotherapy should be closely monitored for disease recurrence by their treating radiation or medical oncologist. Given the relatively indolent behavior of thymomas and risk of late recurrence, patients should be under surveillance for at least 10 years postoperatively. Chest CT is the imaging modality of choice due to its accessibility, high spatial resolution, and sensitivity of detecting early intrathoracic recurrence. When CT findings are equivocal, MRI can help distinguish between benign and malignant processes. FDG‐PET is not routinely indicated as part of the surveillance in patients with thymoma. For patients with low‐risk, Masaoka–Koga stage I thymoma, annual chest CT with contrast should be conducted for 10 years [177]. For patients with high‐risk features (i.e., aggressive histology), R1 (microscopic residual tumor) or R2 (macroscopic residual tumor) resection, and/or Masaoka–Koga stage II–IV thymoma, more intensive surveillance protocols (e.g., chest CT every 6 months) may be appropriate, particularly within the first 6 years postoperatively when the majority of thymoma recurrences occur. Large cohort and long‐term institutional series confirm that thymoma recurrence can occur even after a decade, with rates as high as 10%–20% in patients with Masaoka‐Koga stage III or IV disease who have achieved a complete resection [178, 179]. Continued vigilance may be warranted in such cases. Ultimately, the decision to extend surveillance beyond 10 years should be personalized and include patient preference with respect for autonomy. Treatment Options for Recurrent Thymoma Thymoma recurrence requires a multidisciplinary evaluation best managed in a tumor board setting to discuss radiographic assessment, biopsy technique and treatment options, including surgery, radiation and systemic therapy. Thymoma tends to recur locally, commonly affecting the adjacent pleura [170]. Identification of a growing lesion on surveillance imaging prompts further investigation, often minimally invasive surgical exploration, to confirm the diagnosis, determine the extent of disease and consider more radical resections. Such surgical endeavors include local resection of limited recurrences as well as more aggressive pleurectomy and decortication or extra‐pleural pneumonectomy for diffuse unilateral recurrence. Five‐ and ten‐year survival of selected patients undergoing surgical treatment of thymoma recurrence are 70.9%–82.7% and 49.6%–68.2%, respectively, in available series [180]. Due to the difficulty in achieving an R0 resection for pleural recurrence, multimodal therapy considerations should be discussed in the tumor board. Treatment options could include induction or adjuvant systemic therapy, radiation therapy or the use of heated intrathoracic chemotherapy at the time of surgery [181, 182]. For patients with recurrent metastatic thymoma, palliative systemic therapy is warranted. The preferred option for front‐line therapy is a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). This regimen is associated with high objective response rates (~40%), prolonged survival (> 3 years), and a manageable safety profile [152, 183, 184]. Carboplatin plus paclitaxel and cisplatin plus etoposide are two other effective treatment options with response and survival rates that are similar, but slightly inferior, to CAP. Conclusions The evaluation and management of TAMG requires a multidisciplinary team, and a close collaboration between neurologists, thoracic surgeons, radiologists, radiation oncologists, and oncologists. Successful management of TAMG requires effective treatment of both the underlying thymoma and myasthenic symptoms. There is a need for neurologists to recognize the non‐neurological manifestation of thymoma, the high frequency of asymptomatic AChR antibody in thymoma patients, the basic staging and pathological findings of thymoma, as well as the key radiological features in differentiating thymoma from thymic cysts, thymic hyperplasia, or other common mediastinal tumors. Neurologists should be familiar with the choice of maintenance immunotherapy, the need for adjustment in patients who receive concurrent chemotherapy, as well as providing therapy optimization for patients prior to their surgery. Neurologists also play a role in monitoring the symptomatic progression of MG following thymoma treatment. Ultimately, frequent and direct communication with cardiothoracic surgeons and oncologists is the key in achieving successful long‐term management of TAMG. Author Contributions Yuebing Li: conceptualization, investigation, supervision, funding acquisition, project administration, writing – original draft, writing – review and editing. Benjamin Claytor: conceptualization, data curation, investigation, writing – original draft, writing – review and editing. Erik Seroogy: data curation, writing – original draft, writing – review and editing. Lukas Delasos: data curation, conceptualization, investigation, writing – original draft, writing – review and editing. Jason Lempel: data curation, writing – original draft, writing – review and editing. Daniel P. Raymond: conceptualization, data curation, investigation, writing – original draft, writing – review and editing. Ethics Statement The authors have read and understood Muscle and Nerve Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Conflicts of Interest Dr. Lukas Delasos has consulted for Healio, MJH Life Sciences, Primum, Takeda. Dr. Daniel P. Raymond holds equity interest for Bristol Myers Squibb and Zimmer Biomet and has consulted for KLS Martin. Dr. Yuebing Li has consulted for Alexion, Amgen, Argenx, Johnson & Johnson, Vertex, and has received grant support from Argenx. The other authors declare no conflicts of interest.